SCHEMBL6202791

SCHEMBL6202791

O=C1C2CCC(CN1Cc1ccccc1)C(=O)N(Cc1ccccc1)C2

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.58
HPGD P15428 1/20 0.58
ALDH1A1 P00352 2/20 0.50
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
EHMT2 Q96KQ7 1/20 0.46
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
F2 P00734 1/20 0.44
PLG P00747 1/20 0.44
ELANE P08246 1/20 0.44
CTSG P08311 1/20 0.44
CMA1 P23946 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21789645 0.82 TSHR (0.51) TSHRHPGDALDH1A1CYP3A4CYP2C19
SCHEMBL7226436 0.77 TSHR (0.47) TSHRHPGD
SCHEMBL13986121 0.76 HPGD (0.71) TSHRHPGDCYP2C19MEN1KMT2A
SCHEMBL19518531 0.76 FUCA1 (0.55) TSHRHPGDALDH1A1CYP3A4CYP2C19
SCHEMBL30875889 0.76 FUCA1 (0.55) TSHRHPGDALDH1A1CYP3A4CYP2C19
SCHEMBL20417932 0.76 FUCA1 (0.55) TSHRHPGDALDH1A1CYP3A4CYP2C19
SCHEMBL17560348 0.76 FUCA1 (0.55) TSHRHPGDALDH1A1CYP3A4CYP2C19
SCHEMBL1514852 0.76 FUCA1 (0.55) TSHRHPGDALDH1A1CYP3A4CYP2C19
SCHEMBL10483634 0.75 KMT2A (0.56) TSHRHPGDALDH1A1CYP3A4CYP2C19
SCHEMBL10262574 0.75 TSHR (0.47) TSHRHPGDALDH1A1CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397365-B1 HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS NEUROSEARCH AS (DK) 2005-02-16 EP disclosed
US-20040147505-A1 Novel heteroaryl-diazabicyclo alkanes as cns-modulators NEUROSEARCH A/S (DK) 2004-07-29 US disclosed
EP-1397365-A1 NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS NeuroSearch A/S (DK) 2004-03-17 EP disclosed
WO-2002096911-A1 NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS NEUROSEARCH A/S (DK) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147505-A1 Novel heteroaryl-diazabicyclo alkanes as cns-modulators CHRNA3, CHRNA5, CHRNA2 TSHR 407/4885HPGD 2113/4885ALDH1A1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.